-
Tenecteplase
- indication:For treatment of myocardial infarction and lysis of intracoronary emboli
- pharmacologypharmacology:
- mechanism: Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
- toxicity:
- absorprion:
- halflife: 1.9 hours (mammalian reticulocytes, in vitro) >20 hours (yeast, in vivo) >10 hours (Escherichia coli, in vivo)
- roouteelimination:
- volumedistribution:
- clearance: * 99 - 119 mL/min [acute myocardial infarction patients]